靶向HBV cccDNA的药物及生物技术

陈然; 王杰; 鲁凤民

doi:10.3969/j.issn.1001-5256.2019.06.003

靶向HBV cccDNA的药物及生物技术

DOI: 10.3969/j.issn.1001-5256.2019.06.003

基金项目:

国家“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项“十三五”计划(2017ZX10202202,2017ZX10202203)；北京市自然科学基金(7182080)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2005
- HTML全文浏览量: 50
- PDF下载量: 417
- 被引次数: 0
出版历程
- 收稿日期: 2019-04-24
- 出版日期: 2019-06-20

Advances in drugs and biotechnology targeting hepatitis B virus cccDNA

Research funding:

摘要

摘要: HBV感染是慢性乙型肝炎、肝硬化及肝细胞癌的主要致病因素。HBV共价闭合环状DNA(cccDNA)是HBV复制的模板,能长期稳定存在于肝细胞内,是病毒持续感染的主要因素。核苷(酸)类药物和干扰素等现有的抗病毒药物均不直接靶向cccDNA,故均难以实现慢性乙型肝炎临床治愈。随着生物技术的进步和对HBV cccDNA特性的深入了解,以靶向清除cccDNA为目标的抗病毒治疗研发日益增多,但离临床应用尚有较远的距离。简要综述了HBV cccDNA靶向药物及生物技术相关的研究进展。
- 乙型肝炎病毒 /
- 共价闭合环状DNA /
- 分子靶向治疗
Abstract: Hepatitis B virus (HBV) infection is the main cause of chronic hepatitis B (CHB) , liver cirrhosis, and hepatocellular carcinoma. HBV covalently closed circular DNA (cccDNA) is the template for HBV replication and exists stably in hepatocytes, which is the main factor for persistent infection. However, existing antiviral drugs including nucleos (t) ide analogues and interferons do not directly target cccDNA, and thus it is difficult to achieve the clinical cure of CHB. With the progress in biotechnology and in-depth understanding of the features of HBV cccDNA, more and more studies have been conducted on antiviral therapies targeting cccDNA, but there is still a long way before clinical application. This article briefly reviews related research advances.
- hepatitis B virus /
- cccDNA /
- molecular targeted therapy

HTML全文

参考文献(33)

[1]GISH RG, GIVEN BD, LAI CL, et al.Chronic hepatitis B:Virology, natural history, current management and a glimpse at future opportunities[J].Antiviral Research, 2015, 121:47-58.

[2]CHANG MH, YOU SL, CHEN CJ, et al.Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees:A 20-year follow-up study[J].J Natl Cancer Inst, 2009, 101 (19) :1348-1355.

[3]POLARIS OBSERVATORY C.Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016:A modelling study[J].Lancet Gastroenterol Hepatol, 2018, 3 (6) :383-403.

[4] YAN H, ZHONG G, XU G, et al.Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J].Elife, 2012, 1:e00049.

[5]TRPO C, CHAN HL Y, LOK A.Hepatitis B virus infection[J].The Lancet, 2014, 384 (9959) :2053-2063.

[6]ALTER H, BLOCK T, BROWN N, et al.A research agenda for curing chronic hepatitis B virus infection[J].Hepatology, 2018, 67 (3) :1127-1131.

[7]NASSAL M.HBV cccDNA:Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J].Gut, 2015, 64 (12) :1972-1984.

[8] LUCIFORA J, XIA Y, REISINGER F, et al.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA[J].Science, 2014, 343 (6176) :1221-1228.

[9]BELLONI L, ALLWEISS L, GUERRIERI F, et al.IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome[J].J Clin Invest, 2012, 122 (2) :529-537.

[10]CRADICK TJ, KECK K, BRADSHAW S, et al.Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis Bvirus DNAs[J].Mol Ther, 2010, 18 (5) :947-954.

[11]WEBER ND, STONE D, SEDLAK RH, et al.AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication[J].PLo S One, 2014, 9 (5) :e97579.

[12]BLOOM K, ELY A, MUSSOLINO C, et al.Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases[J].Mol Ther, 2013, 21 (10) :1889-1897.

[13]DREYER T, NICHOLSON S, ELY A, et al.Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus[J].Biochem Bioph Res Commun, 2016, 478 (4) :1563-1568.

[14]LIN SR, YANG HC, KUO YT, et al.The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo[J].Mol Ther Nucleic Acids, 2014, 3 (2162-2531) :e186.

[15]WANG J, XU ZW, LIU S, et al.Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication[J].World JGastroenterol, 2015, 21 (32) :9554-9565.

[16]WANG J, CHEN R, ZHANG R, et al.The gRNA-miRNA-gRNA ternary cassette combining CRISPR/Cas9 with RNAi approach strongly inhibits hepatitis B virus replication[J].Theranostics, 2017, 7 (12) :3090-3105.

[17]QI YH, GAO ZC, XU GW, et al.DNA Polymerase kappa is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus[J].PLo S Pathog, 2016, 12 (10) :e1005893.

[18]ZHANG YM, MAO RC, YAN R, et al.Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpGmethylation during chronic infection[J].PLo S One, 2014, 9 (10) :e110442.

[19]POLLICINO T, BELLONI L, RAFFA G, et al.Hepatitis B virus replication is regulated by the acetylation status of hepatitis Bvirus cccDNA-bound H3 and H4 histones[J].Gastroenterology, 2006, 130 (3) :823-837.

[20]LIU F, CAMPAGNA M, QI Y, et al.Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes[J].PLo S Pathog, 2013, 9 (9) :e1003613.

[21]ZHANG W, CHEN JL, WU M, et al.PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation[J].Hepatology, 2017, 66 (2) :398-415.

[22]WANG J.Epigenetic regulation of HBV covalently closed circular DNA:Implications for epigenetic treatment of chronic hepatitis B[J].Chin Heptol, 2018, 23 (3) :191-193. (In Chinese) 王杰.HBV共价闭合环状DNA的表观遗传调控:对慢性乙型肝炎进行表观遗传治疗的启示[J].肝脏, 2018, 23 (3) :191-193.

[23]XIA YC, STADLER D, LUCIFORA J, et al.Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis[J].Gastroenterology, 2016, 150 (1) :194-205.

[24]BOCKMANN JH, STADLER D, XIA Y, et al.Comparative analysis of the antiviral effects mediated by type I and III interferons in hepatitis B virus infected hepatocytes[J].J Infect Dis, 2019.[Epub ahead of print]

[25]QIAO Y, HAN XX, GUAN GF, et al.TGF-beta triggers HBVcccDNA degradation through AID-dependent deamination[J].Febs Letters, 2016, 590 (3) :419-427.

[26]SITTERLIN D, LEE TH, PRIGENT S, et al.Interaction of the UV-damaged DNA-binding protein with hepatitis B virus Xprotein is conserved among mammalian hepadnaviruses and restricted to transactivation-proficient X-insertion mutants[J].J Virol, 1997, 71 (8) :6194-6199.

[27]van BREUGEL PC, ROBERT EI, MUELLER H, et al.Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates[J].Hepatology, 2012, 56 (6) :2116-2124.

[28]DECORSIRE A, MUELLER H, van BREUGEL PC, et al.Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor[J].Nature, 2016, 531 (7594) :386.

[29]MURPHY CM, XU Y, LI F, et al.Hepatitis B virus X protein promotes degradation of SMC5/6 to enhance HBV replication[J].Cell Rep, 2016, 16 (11) :2846-2854.

[30]SEKIBA K, OTSUKA M, OHNO M, et al.Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBxDDB1 interaction[J].Cell Mol Gastroenterol Hepatol, 2019, 7 (2) :297-312.

[31]KO C, CHAKRABORTY A, CHOU WM, et al.Hepatitis B virus genome recycling and de novosecondary infection events maintain stable cccDNA levels[J].J Hepatol, 2018, 69 (6) :1231-1241.

[32]GUO F, ZHAO Q, SHERAZ M, et al.HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from denovo infection and intracellular amplification pathways[J].PLo S Pathog, 2017, 13 (9) :e1006658.

[33] ZHENG JW, YUAN Q, XIA NS.Progress in potential therapeutic targets and drug development for chronic hepatitis B[J/OL].Acta Microbiologica Sinica, https://doi.org/10.13343/j.cnki.wsxb.20180439. (in Chinese) 郑金伟, 袁权, 夏宁邵.慢性乙型肝炎潜在治疗靶点和新药研发进展[J/OL].微生物学报, https://doi.org/10.13343/j.cnki.wsxb.20180439.

施引文献

资源附件(0)

访问统计